Loading clinical trials...
Loading clinical trials...
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Conditions
Interventions
upifitamab rilsodotin
Locations
1
United States
University of Oklahoma
Oklahoma City, Oklahoma, United States
Start Date
December 12, 2017
Primary Completion Date
July 9, 2021
Completion Date
July 9, 2021
Last Updated
July 24, 2024
NCT07470853
NCT06917573
NCT03774732
NCT03808662
NCT05117242
NCT03907852
Lead Sponsor
Mersana Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions